Back to Search
Start Over
SIRT1 in Secretory Organ Cancer.
- Source :
- Frontiers in Endocrinology; 9/24/2018, pN.PAG-N.PAG, 7p
- Publication Year :
- 2018
-
Abstract
- Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors [1, 2, 3, 4]. A recent meta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression [5]. This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma. Collectively, the meta-analysis revealed that an unfavorable OS was associated with SIRT1 expression for solid malignancies. Given the growing importance of this class of lysine/histone deacetylases in human endocrine malignancies, a rational and focused literature assessment is desirable in light of future clinical translations. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 16642392
- Database :
- Complementary Index
- Journal :
- Frontiers in Endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 131941601
- Full Text :
- https://doi.org/10.3389/fendo.2018.00569